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Abstract
Background: The suppressor of cytokine signaling (SOCS)-3 is a negative feedback regulator of
cytokine signaling and also influences leptin signaling. We investigated association of variations in
the coding sequence and promoter region of SOCS3 with extreme obesity in German children and
adolescents.
Methods:  An initial screen for sequence variations in 181 extremely obese children and
adolescents and 188 healthy underweight adults revealed two previously reported single nucleotide
polymorphisms (SNPs) in the SOCS3 5' region: -1044 C>A (numbering refers to bases upstream
of ATG in exon 2) within a predicted STAT3 binding element and -920 C>A (rs12953258, for
numbering, see above).
Results: We did not detect significant differences in allele or genotype frequencies for any of these
SNPs between the analysed study groups (all nominal p > 0.2). In addition, we performed a pedigree
transmission disequilibrium test (PDT) for the SNP -1044 C>A in families comprising 703 obese
children and adolescents, 281 of their obese siblings and both biological parents. The PDT revealed
no transmission disequilibrium (nominal p > 0.05).
Conclusion: In conclusion, our data do not suggest evidence for a major role of the respective
SNPs in SOCS3 in the pathogenesis of extreme obesity in our study groups.
Background
Obesity is a growing health problem in both developed
and developing countries and a major risk factor for cardi-
ovascular disease. After the discovery of leptin, it was ini-
tially hoped that exogenous leptin therapy might induce
satiety and weight loss in obese humans [1-3]. Inborn lep-
tin deficiency was found to be extremely rare; only within
a few consanguineous families homozygotes for leptin
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deficiency mutations have been detected [4,5]. In these
cases, leptin supplementation normalized eating behav-
iour and reduced fat mass substantially [6-8]. However,
the vast majority of obese individuals display elevated lev-
els of circulating leptin as a consequence of their increased
fat mass [9]. In these obese individuals, the weight loss
achieved with recombinant leptin therapy had at the most
been modest [10].
The fact, that obese individuals did not adequately
respond to increased leptin levels with reduced food
intake implicates that obesity is also influenced by leptin
resistance [11]. One possible mechanism underlying lep-
tin resistance is an inhibition of the intracellular leptin
receptor signaling cascade [12]. Examples for an involve-
ment of the inhibitor molecule suppressor of cytokine sig-
nalling three (SOCS3) in the regulation of leptin signaling
include the following: (i) Exogenous administration of
SOCS3 blocks leptin signaling in cultured cells, whereas
leptin signaling is enhanced by knockdown of Socs3 and a
mutation of the Socs3 binding site on the leptin receptor
[13,14]. (ii) Expression of Socs3 is stimulated by leptin in
cultured cells and in the hypothalamus, suggesting that
high leptin levels attenuate leptin signaling by Socs3
expression [13-17]. (iii) Several rodent models of leptin
resistant obesity exhibit increased Socs3  expression
[13,17]. (iv) The demonstration of leanness and leptin
sensitivity in mice haplo-insufficient for Socs3 and mice
lacking Socs3 in the CNS suggests that Socs-3 limits leptin
action in vivo [18,19].
SOCS3 belongs to the family of cytokine-inducible inhib-
itors of signaling including cytokine-inducible SH2
domain containing protein (CIS) and SOCS1–7 [20].
Members of this family are small proteins containing a N-
terminal region of variable length, a central SH2 domain
and a conserved C-terminal SOCS box [21]. The human
SOCS3 gene maps to chromosome 17q25.3 and consists
of two exons spanning 2,729 nucleotides [22]. The coding
sequence in exon 2 (total of 2,401 nucleotides) comprises
678 nucleotides. The SOCS3 minimal promoter is 128 bp
in length and consists of two adjacent STAT-binding ele-
ments (SBE), a G/C-rich element, and a putative TATA box
[23]. These elements are highly conserved in both murine
and rat Socs3 promoters [24,25].
Given the importance of leptin in body weight regulation,
this study was undertaken to determine whether varia-
tions in the coding sequence (CDS) or promoter region of
SOCS3 are associated with early onset obesity in a Ger-
man population. We hypothesized that genetic variations,
leading to an altered expression or function of SOCS3
could affect energy homeostasis through an influence on
leptin signaling and thus predispose an individual
towards the development of obesity.
Methods
Study subjects
The ascertainment strategy was previously described in
detail [26]. All extremely obese children and adolescents
had an age and gender specific BMI percentile of 97 or
higher, the BMI of the underweight students was below
the 15 th percentile, as previously determined in a repre-
sentative German population sample [27]. Inclusion crite-
ria for the underweight students additionally included:
(a) absence of somatic disorders, and (b) consumption ≤
10 cigarettes per day. Study group 1 comprised 181
extremely obese German children and adolescents who
were recruited in hospitals specialised for treatment of
young in-patients with extreme obesity. Study group 2
included 278 healthy underweight students who were
recruited at the University of Marburg. The latter were
reimbursed for their voluntary participation.
The family/trio sample included 703 families comprising
a total of 984 extremely obese children and adolescents;
their obese siblings and both biological parents.
Study groups 1, 2 and the family/trio sample were inde-
pendent of each other. Table 1 shows the descriptive sta-
tistics of the genotyped individuals. All participants were
Germans from a homogeneous population of European
descent.
Written informed consent was given by all participants
and, in the case of minors, their parents. This study was
approved by the Ethics Committee of the University of
Marburg and carried out in accordance with the Declara-
tion of Helsinki.
Molecular genetic methods
We designed three primer pairs to amplify the entire cod-
ing region (exon 2) of SOCS3. Primers were derived from
a genomic sequence (GenBank accession no: NC_000017;
28) as follows: SOCS3-3d-F: 5' GTT CCG GGC ACT CAA
CG 3' and SOCS3-3d-R: 5' CAG CTT GAG CAC GCA GTC
3': 497 bp SOCS3-3d amplicon. SOCS3-3-F: 5' AGT CTG
GGA CCA AGA ACC TG 3' and SOCS3-3-R: 5' CTT GTG
CTT GTG CCA TGT G 3': 499 bp SOCS3-3 amplicon. To
amplify the minimal promoter region [23], we designed
following primer pair: SOCS3-prom-F: 5' CTC GTC GCG
CTT TGT CT 3' and SOCS3-prom-R: 5' GGG AGG GGA
CCA GGA G 3': 344 bp SOCS3-prom amplicon. Polymer-
ase chain reaction (PCR) was performed according to
standard protocols. The SOCS3-3d amplicon was digested
with GsuI (Fermentas, resulting in fragments of 274 bp
and 223 bp) and the SOCS3-3 amplicon was digested
with NaeI (NEB, resulting in fragments of 279 bp and 220
bp). Single strand conformation polymorphism analysis
(SSCP) was performed at ambient temperature and at
4°C, to increase the mutation detection sensitivity asBMC Medical Genetics 2007, 8:21 http://www.biomedcentral.com/1471-2350/8/21
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described previously [29]. All PCR amplicons with SSCP
patterns deviant from the wild-type pattern were re-
sequenced as described previously [29]. To genotype -
1044 C>A, PCR with subsequent diagnostic restriction
length polymorphism analyses (RFLP) was performed:
the 344 bp PCR amplicon SOCS3-prom was digested by
Mva I (NEB; C-allele: 12, 157 and 175 bp, A-allele: 12 and
332 bp). To genotype rs12953258 (-920 C>A) we per-
formed tetra-ARMS-PCR [30] with following primers: C-
920A-o-F: 5' CCG CGC TCA GCC TTT CTC TGC TGC GA
3'; C-920A-o-R: 5' AGT CCA CAA AGG AGC CTT CGC
GCG CG 3'; C-920A-i-F: 5' CCC GCA CGC AGC CAG
CCG TCC 3'; C-920A-i-R: 5' AGC TGG GCC GGG CGG
GCG ACT 3'. Sizes of the PCR products were 338 bp (outer
primer pair), 210 bp (A-allele) and 170 bp (C-allele). All
PCR products were visualized on ethidium bromide-
stained 2.5% agarose gels. Allele sizes were determined
with a molecular weight standard (123 bp ladder, Gibco
BRL, Karlsruhe, Germany). Positive controls for the vari-
ant alleles were run on each gel. For validity of the geno-
types, allele determinations were rated independently by
at least two experienced individuals. Discrepancies were
resolved unambiguously either by reaching consensus or
by re-typing.
Statistical analysis
Differences in genotype and allele frequencies between
the independent study groups 1 and 2 were investigated
using Fisher's exact test and in the case of genotypes the
Cochran-Armitage Trend test. The pedigree transmission
disequilibrium [PDT; 31] was performed for family-based
analyses using UNPHASED [32] and estimates of genetic
effects were derived according to Cordell and Clayton
[33]. Power calculations were done with the software
QUANTO Version 1.0 [34] for the situation of common
variants. 180 case-control pairs were estimated to yield a
power of 0.80 to detect a multiplicative genotype relative
risk of 1.87 (α = 0.05; two-sided) assuming a minor allele
frequency (MAF) of 0.1. For the family-based approach
(700 trio families) the power estimate was 0.8 to detect a
multiplicative genotype relative risk of 1.4 (α = 0.05; two-
sided) again assuming a MAF of 0.1. Thus, the study was
well powered to detect common disease predisposing var-
iants of moderate effects. All genotype distributions were
tested for Hardy Weinberg equilibrium (HWE) using
PEDSTATS 0.6.4 [35] and no evidence for such deviations
was detected (all p > 0.4). The level α for each test was
0.05 (two-sided) and due to the fact that we were not able
to find evidence for a significant association, no correc-
tion for multiple testing was considered. If not mentioned
otherwise, all reported p-values are nominal, two-sided
and exact.
Results
In the study groups comprising 181 extremely obese chil-
dren and adolescents (study group 1) and 188 healthy
underweight controls (study group 2) we detected two
previously described SNPs: -1044 C>A; 36) within the
promoter region and rs12953258 (-920 C>A; 37) in the
5'UTR (exon 1) of SOCS3.
We did not identify any sequence variants within the cod-
ing region. The linkage disequilibrium (r2) between the
two markers (-1044 C>A) and rs12953258 (-920 C>A))
derived by FAMHAP (Version 16) [38] was <0.002 imply-
ing that they are largely independent. Evidence for differ-
ences in allele and genotype frequencies were not detected
for the two SNPs between 181 extremely obese children
and adolescents and 278 underweight subjects (all p >
0.2; table 2). Because of its potential functional conse-
quences we additionally genotyped -1044 C>A in families
comprising 703 extremely obese children and adoles-
cents, 281 of their obese siblings and both biological par-
ents. The pedigree transmission disequilibrium test (PDT)
revealed 16 transmissions and 21 non-transmissions of
the A-allele to the obese offspring (asymptotic p (SUM-
PDT) = 0.3) which corresponds to an estimated genetic
effect (odds ratio) of 0.76 with a 95% confidence interval
(0.45–1.29) for heterozygous carriers compared to CC
homozygous. The A-allele frequency estimated in the par-
Table 1: Descriptive statistics (frequencies, means, standard deviations) for the investigated case-control and family sample.
sample# n* age [years] BMI [kg/m2] weight [kg] height [cm] waist hip ratio lg [leptin]
underweight adults 278 24.98 (3.69) 18.24 (1.11) 59.13 (8.68) 176.66 (9.65) 0.79 (0.42) 0.23 (1.13)
female 142 24.61 (3.40) 17.55 (0.77) 51.98 (4.30) 169.90 (6.49) 0.79 (0.59) 1.21 (0.64)
male 136 25.37 (3.93) 18.96 (0.94) 65.63 (6.19) 183.72 (6.99) 0.80 (0.05) -0.52 (0.80)
extremely obese children and adolescents 181 14.31 (2.40) 35.60 (6.12) 99.05 (24.93) 165.95 (11.78) 0.91 (0.10) 3.25 (0.60)
female 91 14.61 (2.41) 35.93 (6.59) 98.33 (23.51) 164.63 (9.94) 0.85 (0.08) 3.44 (0.48)
male 90 14.01 (2.37) 35.25 (5.64) 99.80 (26.42) 167.30 (13.33) 0.97 (0.09) 3.02 (0.65)
extremely obese offspring within 703 families 984 14.00 (3.69) 31.05 (5.98) 83.55 (24.26) 162.42 (14.10) 0.90 (0.09) 3.06 (0.75)
female offspring 543 14.01 (3.78) 31.27 (6.27) 81.58 (23.89) 159.89 (12.92) 0.86 (0.08) 3.19 (0.63)
male offspring 441 13.99 (3.59) 30.79 (5.60) 85.98 (24.52) 165.54 (14.85) 0.93 (0.08) 2.95 (0.85)
# all subjects were recruited in Germany and all self-reported to be of European descent
* maximum number of observations for each variableBMC Medical Genetics 2007, 8:21 http://www.biomedcentral.com/1471-2350/8/21
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ents was 0.86% with a 95% confidence interval (0.55%–
1.27%).
Discussion
Here we report an association study of SOCS3 sequence
variations in body weight regulation in humans. We sys-
tematically screened the CDS and the minimal promoter
of the human SOCS3 gene for sequence variations. In our
study groups comprising 181 extremely obese children
and adolescents and 188 healthy underweight adults we
did not identify sequence variants within the CDS. Note
that the screening sample size is sufficient to allow for the
detection of common variants (e.g. when estimating a
MAF of 0.05 a sample size of n = 180 produces a 95% con-
fidence interval with a precision of +/- 0.02). In the
SOCS3 minimal promoter region we identified the SNP -
1044 C>A and in the 5'UTR (exon 1) the SNP
rs12953258. Both SNPs were previously described with a
minor allele frequency of 8% (rs12953258) and below
1% (-1044 C>A) in Danish individuals [36].
In a group of 360 population-based young healthy sub-
jects the insulin sensitivity index was higher among
homozygous carriers of the A-allele of rs12953258 than
among heterozygous and wild-type subjects (p = 0.027,
uncorrected; 36). However, an effect on BMI was not
detected. A very recent large study did not find association
between rs12953258 and two other SNPs (rs4969169 and
rs8064821) in SOCS3 and obesity, insulin or lipid meas-
ures [39]. The study comprised 2,777 female twins of
European descent, who were not ascertained for obesity or
elevated body weight. This finding can be considered as
representative of the UK female population. Both previ-
ous studies [36,39] were performed on population-based
study groups; both did not find association of the
rs12953258 alleles with obesity, which is in line with our
findings. As our study relies on extremely obese individu-
als our results additionally to the previous results showed
that the SNP is also not relevant for extreme obesity.
Our comparison of 181 extremely obese children and
adolescents and 278 underweight adults revealed no evi-
dence for an association for rs12953258. SNP -1044 C>A
is located within the proximal SBE where the A-allele
destroys the specific palindromic STAT binding motif
TTCCAGGAA resulting in TTACAGAA. Previous studies
on the SOCS3 promoter indicated that particularly the
proximal SBE is functionally relevant for promoter activity
[24,25,40,41]. We hypothesized, that the -1044 C>A vari-
ant might result in the loss of a STAT3 binding site and
thus influence the leptin dependent transcriptional activa-
tion of SOCS3. In our case-control association study we
also compared allele and genotype frequencies of -1044
C>A. However, no evidence for an association with obes-
ity was detected. Because of the potential functional role
of this SNP and its infrequency we additionally performed
PDT analyses in 703 families comprising 984 extremely
obese children and adolescents and their obese siblings
and both biological parents. The test revealed no evidence
for transmission disequilibrium. However, the potential
relevance of this variation in gene regulation warrants
comparative functional studies.
We tried to answer the question if our finding negative
because the selected SNPs had no effect on SOCS3 expres-
sion/function, or if variable SOCS3 expression/function
has no effect on obesity. Gylvin et al. [36]in silico analysed
that the -920 A allele deletes an activator protein 2 (AP2)
transcription factor binding site. AP2 is involved in angio-
genesis, tumour invasion/metastasis and chronic inflam-
mation [42]. Additionally, the TRANSFAC database [43]
also shows that the rs12953258 C-allele destroys a site
bound by ZNF202, a transcriptional repressor, binding to
elements found predominantly in genes that participate
in lipid metabolism and therefore remains a variant of
potential significance in SOCS3 action in lipid metabo-
lism. Although there was no association between SOCS3
SNPs and obesity, this does not exclude a strong genetic
determination of SOCS3 variability. The lack of associa-
tion between the SOCS3 SNPs and obesity is probably
because they are not in LD with a functional site.
Table 2: Genotype distributions and estimates for the polymorphisms -1044 C>A and -920 A>C in the vicinity of SOCS3 for the case-
control sample (percentages in parenthesis).
SOCS3 marker underweight adults 
(n = 278)
extremely obese children 
and adolescents (n = 181)
estimated genotype odds ratio 
[exact 95% confidence interval]
estimated minor allele frequency in cases 
[Clopper- Pearson 95% confidence interval]
-920 C>A
CC 235 (84.53%) 144 (79.56%)
CA 40 (14.39%) 35 (19.34%) 1.43 [0.84–2.42] 10.77% [7.77%–14.43%]
AA 3 (1.08%) 2 (1.10%) 1.09 [0.09–9.61]
-1044 C>A
CC 270 (97.12%) 174 (96.13%)
CA 8 (2.88%) 7 (3.87%) 1.36 [0.41–4.37] 1.93% [0.78%–3.94%]
AA 0 (0%) 0 (0%) -BMC Medical Genetics 2007, 8:21 http://www.biomedcentral.com/1471-2350/8/21
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Our study does not exclude the possibility that functional
variants exist in the SOCS3 gene, which influence expres-
sion and function. On the basis of biological evidence,
SOCS3 remains a strong candidate in this respect.
Conclusion
Our results do not suggest a major role of the analysed
SNPs in SOCS3 in early onset obesity. However, the rele-
vance of this variation in gene regulation warrants func-
tional studies. Since obesity is viewed as a polygenic
disorder, products of numerous genes may be involved.
To exclude moderate effects of the investigated sequence
variations in body weight regulation large samples need
to be assessed.
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